Abstract
Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related recurrences and subsequent deaths. With such a dismal prognosis, there is an expanding role for novel targeted approaches in the treatment of USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. The results emphasize the relevance of these novel therapeutic targets for biologic therapy of USC, which will be reviewed in this article.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors
-
Class I Phosphatidylinositol 3-Kinases / genetics
-
Cyclin E / antagonists & inhibitors
-
Cyclin E / genetics
-
Cystadenocarcinoma, Serous / genetics
-
Cystadenocarcinoma, Serous / mortality
-
Cystadenocarcinoma, Serous / pathology
-
Cystadenocarcinoma, Serous / therapy*
-
Endometrial Neoplasms / genetics
-
Endometrial Neoplasms / mortality
-
Endometrial Neoplasms / pathology
-
Endometrial Neoplasms / therapy*
-
Epothilones / therapeutic use
-
Exome / genetics
-
Female
-
Humans
-
Molecular Targeted Therapy / methods*
-
Mutation
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / mortality
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / therapy*
-
Oncogene Proteins / antagonists & inhibitors
-
Oncogene Proteins / genetics
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Phosphatase 2 / genetics
-
Radioimmunotherapy
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / genetics
-
Sequence Analysis, DNA
-
Signal Transduction / drug effects*
-
Signal Transduction / genetics
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
TOR Serine-Threonine Kinases / genetics
-
Tubulin Modulators / therapeutic use
-
Tumor Suppressor Protein p53 / genetics
-
Uterine Neoplasms / genetics
-
Uterine Neoplasms / mortality
-
Uterine Neoplasms / pathology
-
Uterine Neoplasms / therapy*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
CCNE1 protein, human
-
Cyclin E
-
Epothilones
-
Oncogene Proteins
-
PPP2R1A protein, human
-
Protein Kinase Inhibitors
-
TP53 protein, human
-
Tubulin Modulators
-
Tumor Suppressor Protein p53
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
MTOR protein, human
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CA protein, human
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
TOR Serine-Threonine Kinases
-
Protein Phosphatase 2